Chronic respiratory diseases such as chronic obstructive pulmonary disease and asthma are on the rise in many countries, including low-income and middle-income countries such as Kenya that also have a sizeable burden of tuberculosis. What does this mean for patients in terms of the affordability of potentially long-term management? How are government-run social health insurance schemes working for individuals and their families? And what might be the individual-level drivers of catastro...
All content for The Lancet Global Health in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Chronic respiratory diseases such as chronic obstructive pulmonary disease and asthma are on the rise in many countries, including low-income and middle-income countries such as Kenya that also have a sizeable burden of tuberculosis. What does this mean for patients in terms of the affordability of potentially long-term management? How are government-run social health insurance schemes working for individuals and their families? And what might be the individual-level drivers of catastro...
Chronic respiratory diseases such as chronic obstructive pulmonary disease and asthma are on the rise in many countries, including low-income and middle-income countries such as Kenya that also have a sizeable burden of tuberculosis. What does this mean for patients in terms of the affordability of potentially long-term management? How are government-run social health insurance schemes working for individuals and their families? And what might be the individual-level drivers of catastro...
